CDEK
← All drugs Report issue

abbv-181

mAbexperimental

Clinical trial activity

7 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
7
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started Dec 20, 2016 (NCT03000257)

Timeline

2010s

  1. Jan 1, 2016

    Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Also known as

  • abbv-181

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04223804Phase 1Jan 17, 2020AbbVie
NCT04196283Phase 1Dec 14, 2019AbbVie, Aceragen, Inc/
NCT03893955Phase 1May 21, 2019AbbVie
NCT03818542Phase 1Mar 8, 2019AbbVie
NCT03821935Phase 1Feb 21, 2019AbbVie
NCT03639194Phase 1Sep 3, 2018AbbVie
NCT03000257Phase 1Dec 20, 2016AbbVie
Showing 7 of 7 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
AbbVieFor profit7712016
Aceragen, Inc/For profit1012019
2 organizations
Page 1 / 1